On 29 July 2004, orphan designation (EU/3/04/208) was granted by the European Commission to Bayer Vital GmbH, Germany, for acetylsalicylic acid for the treatment of polycythemia vera.
- What is polycythemia vera?
Polycythemia vera is a disorder characterized by excessive and uncontrolled production of red blood cells, but also white blood cells and platelets, in the bone marrow. This feature of "too many blood cells" results in unique symptoms and complications. Persons with polycythemia vera are at higher risk of clotting or bleeding problems related to the resulting increased blood volume and viscosity (thickness). Symptoms caused by the elevated cell numbers such as headache, dizziness, visual disturbances, inability to concentrate and paresthesis (numbness) are present initially in 30 to 50% of patients. Affected persons typically develop an enlarged liver and spleen and may present with itching skin and gout. The increased number of cells in the blood can lead to formation of blood clots which impair the blood circulation and can result in necrosis of organs. Polycythemia vera is a chronically debilitating and life-threatening condition.
- What are the methods of treatment available?
Other medicinal products were authorised for the treatment of polycythemia vera within the Community at the time of submission of the application for orphan drug designation. Satisfactory argumentation has been submitted by the sponsor to justify the assumption that the medicinal product might be of potential significant benefit for the treatment of polycythemia vera, particularly in terms of preventing thrombosis (blood clot formation). The assumption will have to be confirmed at the time of marketing authorisation. This will be necessary to maintain the orphan status.
- What is the estimated number of patients affected by the condition*?
According to the information provided by the sponsor, polycythemia vera was considered to affect about 92,000 to 138,000 persons in the European Union.
*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed based on data from the European Union (EU 25), Norway, Iceland and Lichtenstein. This represents a population of 459,700,000 (Eurostat 2004). This estimate is based on available information and calculations presented by the sponsor at the time of the application.
- How is this medicinal product expected to act?
Platelets are blood cells taking part in the formation of blood clots. These blood components are for example, fundamental in the rapid formation of the clot to stop the bleeding in injuries. Acetylsalicylic acid (Aspirin) is known to interfere with this platelet function by inhibiting the synthesis of a substance called thromboxan that stimulates the formation of blood clots. So, in polycythemia patients acetylsalicylic acid (Aspirin) would reduce the risk of clot formation.
- What is the stage of development of this medicinal product?
At the time of submission of the application for orphan designation, clinical trials in patients with polycythemia vera were completed. Acetylsalicylic acid was not marketed anywhere worldwide for polycythemia vera or designated as orphan medicinal product elsewhere for this condition, at the time of submission. According to Regulation (EC) No 141/2000 of 16 December 1999, the Committee for Orphan Medicinal Products (COMP) adopted on 16 June 2004 a positive opinion recommending the grant of the above-mentioned designation.
- Opinions on orphan medicinal products designations are based on the following cumulative criteria:
- the seriousness of the condition,
- the existence or not of alternative methods of diagnosis, prevention or treatment and
- either the rarity of the condition (considered to affect not more than five in ten thousand persons in the Community) or the insufficient return of development investments.
Designated orphan medicinal products are still investigational products which were considered for designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of the quality, safety and efficacy will be necessary before this product can be granted a marketing authorisation.
|Name||Language||First published||Last updated|
|EU/3/04/208: Public summary of positive opinion for orphan designation of acetylsalicylic acid for the treatment of polycythemia vera||(English only)||2004-12-06|
|Active substance||Acetylsalicylic acid|
|Disease/condition||Treatment of polycythemia vera|
|Date of decision||29/07/2004|
|Orphan decision number||EU/3/04/208|
Review of designation
Sponsor’s contact details
Bayer Vital GmbH
Tel. +49 2203 56 82 53
Fax +49 2203 56 83 73
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.